Nivolumab plus ipilimumab in melanoma brain metastases-Reference-Cited by-同舟云学术

Nivolumab plus ipilimumab in melanoma brain metastases

Published:2022-02 Issue:2 Volume:23 Page:e53
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Di Giacomo Anna Maria,Maio Michele

Funder

Bristol-Myers Squibb Co

Fondazione Italiana per la Ricerca sul Cancro Airc

Publisher

Elsevier BV

Subject

Oncology

Reference4 articles.

1. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study;Tawbi;Lancet Oncol,2021

2. Five-year overall survival from anti-PD-1 brain collaboration (ABC study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets);Long;Proc Am Soc Clin Oncol,2021

3. Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases;Di Giacomo;Clin Cancer Res,2021

4. Immunotherapy of brain metastases: breaking a “dogma”;Di Giacomo;J Exp Clin Cancer Res,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective;Expert Opinion on Biological Therapy;2024-03-03

2. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial;European Journal of Cancer;2024-03

3. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401;Journal of Clinical Oncology;2023-08-10

4. Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis;Immunopharmacology and Immunotoxicology;2023-05-25

5. Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis;Med;2022-12